Texas Oncology-Grapevine
Grapevine, Texas 76053
3 studies enrolling now · 14 studies all time
What they study most
Breast Adenocarcinoma, Breast Cancer, Breast Ductal Carcinoma In Situ, Cancer, Chronic Lymphocytic Leukemia (CLL), Estrogen Receptor Negative, Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Studies at this site
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) — Recruiting now
- A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer — Recruiting now
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
- Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy — Running, not enrolling
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — Running, not enrolling
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer — Completed
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy — Completed
- Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
- The Circulating Cell-free Genome Atlas Study — Status unconfirmed
- A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors — Completed
- informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
- Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors — Completed
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer — Completed
- A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer — Stopped early